In DEFINE study anacetrapib also increased HDL-C by 138%, if HDL is active it might compensate, but if the benefit of anacetrapib on reduction in CV events is solely derived from LDL-C reduction, then this of course bearish.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.